Alan B. Sandler

Alan B. Sandler's AcademicInfluence.com Rankings

Alan B. Sandler

Philosophy

#6439

World Rank

#9474

Historical Rank

Logic

#3603

World Rank

#4792

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Alan B. Sandler's Degrees

Doctorate Medicine Harvard University

Why Is Alan B. Sandler Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Alan B. Sandler's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. (2006) (5665)
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. (2002) (4832)
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial (2017) (3388)
Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. (2003) (2609)
Atezolizumab for First‐Line Treatment of Metastatic Nonsquamous NSCLC (2018) (2238)
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial (2016) (2154)
First‐Line Atezolizumab plus Chemotherapy in Extensive‐Stage Small‐Cell Lung Cancer (2018) (1653)
TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. (2005) (1538)
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. (2019) (806)
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab (2018) (786)
Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. (2000) (734)
Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC. (2020) (587)
Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. (1997) (551)
Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. (2005) (533)
Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. (2006) (499)
Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. (2007) (415)
Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial - E4599 (2005) (379)
Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. (2008) (350)
Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook. (2020) (338)
Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). (2017) (306)
Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. (2008) (300)
Endoscopic Ultrasonography, Fine-Needle Aspiration Biopsy Guided by Endoscopic Ultrasonography, and Computed Tomography in the Preoperative Staging of Non-Small-Cell Lung Cancer: A Comparison Study (1997) (287)
Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer. (2013) (286)
Cell Adhesion Molecules, Vascular Endothelial Growth Factor, and Basic Fibroblast Growth Factor in Patients with Non–Small Cell Lung Cancer Treated with Chemotherapy with or without Bevacizumab—an Eastern Cooperative Oncology Group Study (2008) (267)
Epidermal growth factor receptor: a promising target in solid tumours. (2004) (257)
Angiogenesis and lung cancer: prognostic and therapeutic implications. (2005) (253)
Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594 (2001) (245)
Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer. (2015) (238)
A Multicenter Phase II Study of Ganetespib Monotherapy in Patients with Genotypically Defined Advanced Non–Small Cell Lung Cancer (2013) (232)
Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. (2010) (222)
Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. (2008) (216)
Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous Non-Small-Cell Lung Cancer (IMpower131): Results From a Randomized Phase III Trial. (2020) (213)
IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC. (2018) (212)
Inhibition of Poly(ADP-Ribose) Polymerase Enhances Cell Death and Improves Tumor Growth Delay in Irradiated Lung Cancer Models (2007) (211)
Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial. (2015) (203)
TRIBUTE - A phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC). (2004) (179)
Treatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines (2nd edition). (2007) (176)
Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non–Small Cell Lung Cancer (2018) (175)
Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study. (2009) (164)
Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell Lung Cancer (2010) (161)
Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti–PD-L1) (2018) (160)
Invisible barriers to clinical trials: the impact of structural, infrastructural, and procedural barriers to opening oncology clinical trials. (2006) (155)
Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: a Hoosier Oncology Group study. (1995) (155)
A Phase I and Pharmacokinetic Study of the Oral Histone Deacetylase Inhibitor, MS-275, in Patients with Refractory Solid Tumors and Lymphomas (2008) (155)
Chemotherapy in Non-Small Cell Lung Cancer (2000) (152)
Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab. (2009) (150)
Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) Study. (2004) (147)
Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501. (2009) (141)
Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer. (2012) (134)
OA05.07 IMpower132: PFS and Safety Results with 1L Atezolizumab + Carboplatin/Cisplatin + Pemetrexed in Stage IV Non-Squamous NSCLC (2018) (133)
Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732. (2005) (132)
Survival Differences by Sex for Patients with Advanced Non-small Cell Lung Cancer on Eastern Cooperative Oncology Group Trial 1594 (2006) (132)
Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy. (2007) (129)
Anti-Vascular Endothelial Growth Factor Monoclonals in Non-Small Cell Lung Cancer (2004) (129)
Role of computed tomography in the staging of primary melanoma. (1993) (126)
Targeting Cyclooxygenase-2 in Recurrent Non–Small Cell Lung Cancer: A Phase II Trial of Celecoxib and Docetaxel (2005) (121)
A Phase I Trial of a Potent P-Glycoprotein Inhibitor, Zosuquidar Trihydrochloride (LY335979), Administered Intravenously in Combination with Doxorubicin in Patients with Advanced Malignancy (2004) (120)
Randomized Phase III Trial Comparing Single-Agent Paclitaxel Poliglumex (CT-2103, PPX) with Single-Agent Gemcitabine or Vinorelbine for the Treatment of PS 2 Patients with Chemotherapy-Naïve Advanced Non-small Cell Lung Cancer (2008) (118)
COX-2 inhibition and lung cancer. (2004) (118)
Phase I Study of Inhaled Doxorubicin for Patients with Metastatic Tumors to the Lungs (2007) (116)
Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group Trial 1597. (2003) (115)
Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function. (2006) (100)
Gemcitabine: single-agent and combination therapy in non-small cell lung cancer. (1999) (99)
FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open‐Label Study of Atezolizumab in PD‐L1–Selected Patients With NSCLC (2018) (98)
Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study. (2019) (97)
A Phase I Trial of TNFerade Biologic in Patients with Soft Tissue Sarcoma in the Extremities (2004) (93)
Clinical activity, safety and predictive biomarkers of the engineered antibody MPDL3280A (anti-PDL1) in non-small cell lung cancer (NSCLC): update from a phase Ia study. (2015) (89)
Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2L/3L NSCLC (2016) (88)
Body Mass Index and Its Association with Clinical Outcomes for Advanced Non–Small-Cell Lung Cancer Patients Enrolled on Eastern Cooperative Oncology Group Clinical Trials (2013) (87)
Long-term survival in patients with advanced non-small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study. (2019) (86)
Blood-Based Biomarkers for Cancer Immunotherapy: Tumor Mutational Burden in Blood (bTMB) is Associated with Improved Atezolizumab (atezo) Efficacy in 2L+ NSCLC (POPLAR and OAK) (2017) (85)
Clinical activity and safety from a phase II study (FIR) of MPDL3280A (anti-PDL1) in PD-L1–selected patients with non-small cell lung cancer (NSCLC). (2015) (82)
Phase I study of thoracic radiation dose escalation with concurrent chemotherapy for patients with limited small-cell lung cancer: Report of Radiation Therapy Oncology Group (RTOG) protocol 97-12. (2005) (82)
OA20.01 Tumor Mutation Burden (TMB) is Associated with Improved Efficacy of Atezolizumab in 1L and 2L+ NSCLC Patients (2017) (80)
A Phase II Study of Celecoxib in Combination with Paclitaxel, Carboplatin, and Radiotherapy for Patients with Inoperable Stage IIIA/B Non–Small Cell Lung Cancer (2009) (79)
Combining Targeted Agents: Blocking the Epidermal Growth Factor and Vascular Endothelial Growth Factor Pathways (2006) (78)
Overall survival (OS) analysis of IMpower150, a randomized Ph 3 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous (NSQ) NSCLC. (2018) (76)
Processes to activate phase III clinical trials in a Cooperative Oncology Group: the Case of Cancer and Leukemia Group B. (2006) (75)
State of the Art in Therapy for Non-Small Cell Lung Cancer (2005) (75)
Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study (2018) (75)
16LBA Phase II, single-arm trial (BIRCH) of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1-selected non-small cell lung cancer (NSCLC) (2015) (75)
Cigarette smoking history predicts sensitivity to erlotinib: Results of a phase II trial in patients with bronchioloalveolar carcinoma (BAC). (2004) (74)
Combined cisplatin and gemcitabine for non-small cell lung cancer: influence of scheduling on toxicity and drug delivery. (1998) (72)
Clinical utility of EUS-guided fine-needle aspiration of mediastinal masses in the absence of known pulmonary malignancy. (2002) (67)
Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer. (2003) (66)
Non-small cell lung cancer and antiangiogenic therapy: what can be expected of bevacizumab? (2004) (66)
A phase II, multicenter, randomized clinical trial to evaluate the efficacy and safety of bevacizumab in combination with either chemotherapy (docetaxel or pemetrexed) or erlotinib hydrochloride compared with chemotherapy alone for treatment of recurrent or refractory non-small cell lung cancer. (2006) (65)
Prognostic Models to Predict Survival in Non–Small-Cell Lung Cancer Patients Treated with First-Line Paclitaxel and Carboplatin with or without Bevacizumab (2012) (65)
IMpower130: Progression-free survival (PFS) and safety analysis from a randomised phase III study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab (atezo) as first-line (1L) therapy in advanced non-squamous NSCLC. (2018) (64)
A phase II multicenter study of L-alanosine, a potent inhibitor of adenine biosynthesis, in patients with MTAP-deficient cancer (2009) (62)
The role of MET receptor tyrosine kinase in non-small cell lung cancer and clinical development of targeted anti-MET agents. (2013) (61)
Phase III Clinical Trial Development: A Process of Chutes and Ladders (2010) (60)
Inhibition of angiogenesis in the treatment of non‐small cell lung cancer (2007) (58)
Sex Differences in Outcome with Bevacizumab Therapy: Analysis of Patients with Advanced-Stage Non-small Cell Lung Cancer Treated with or without Bevacizumab in Combination with Paclitaxel and Carboplatin in the Eastern Cooperative Oncology Group Trial 4599 (2011) (58)
Long survival of never smoking non-small cell lung cancer (NSCLC) patients (pts) treated with erlotinib HCl (OSI-774) and chemotherapy: Sub-group analysis of TRIBUTE. (2004) (57)
Vascular endothelial growth factor tyrosine kinase inhibitor AZD2171 and fractionated radiotherapy in mouse models of lung cancer. (2006) (56)
Bevacizumab Maintenance in Patients with Advanced Non–Small-Cell Lung Cancer, Clinical Patterns, and Outcomes in the Eastern Cooperative Oncology Group 4599 Study: Results of An Exploratory Analysis (2012) (55)
Development of Clinical Trials in a Cooperative Group Setting: The Eastern Cooperative Oncology Group (2008) (54)
The Potential Predictive Value of Cyclooxygenase-2 Expression and Increased Risk of Gastrointestinal Hemorrhage in Advanced Non–Small Cell Lung Cancer Patients Treated with Erlotinib and Celecoxib (2008) (54)
Patient‐Reported Outcomes in OAK: A Phase III Study of Atezolizumab Versus Docetaxel in Advanced Non–Small‐cell Lung Cancer (2018) (53)
VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab. (2010) (53)
Salvage therapy for advanced non-small cell lung cancer: factors influencing treatment selection. (2006) (52)
Phase 1b Study of Motesanib, an Oral Angiogenesis Inhibitor, in Combination with Carboplatin/Paclitaxel and/or Panitumumab for the Treatment of Advanced Non–Small Cell Lung Cancer (2009) (51)
Bevacizumab and erlotinib: a promising new approach to the treatment of advanced NSCLC. (2008) (50)
Chemotherapy for small cell lung cancer. (2003) (50)
Summary Statement: Novel Agents in the Treatment of Lung Cancer: Advances in Epidermal Growth Factor Receptor-Targeted Agents (2006) (49)
The epidemiology of lung cancer. (2001) (49)
Is retroperitoneal lymph node dissection necessary for adult paratesticular rhabdomyosarcoma? (1998) (49)
Tumor mutation load assessed by FoundationOne (FM1) is associated with improved efficacy of atezolizumab (atezo) in patients with advanced NSCLC (2016) (48)
Cervical primitive neuroectodermal tumor. (2001) (48)
Preliminary phase II safety evaluation of ZD6474, in combination with carboplatin and paclitaxel, as 1st-line treatment in patients with NSCLC (2005) (46)
Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with EGFR mutations (2019) (46)
Select clinical trials of erlotinib (OSI-774) in non-small-cell lung cancer with emphasis on phase III outcomes. (2004) (46)
EGFR mutation and copy number, EGFR protein expression and KRAS mutation as predictors of outcome with erlotinib in bronchioloalveolar cell carcinoma (BAC): Results of a prospective phase II trial. (2006) (46)
Isolating the Role of Bevacizumab in Elderly Patients With Previously Untreated Nonsquamous Non–Small Cell Lung Cancer (2015) (44)
Efficacy and safety of axitinib (AG-013736; AG) in patients (pts) with advanced non-small cell lung cancer (NSCLC): A phase II trial (2007) (44)
The influence of gemcitabine and cisplatin schedule on response and survival in advanced non-small cell lung cancer. (2000) (43)
A phase II study of weekly gemcitabine and paclitaxel in patients with previously untreated stage IIIb and IV non-small cell lung cancer. (2002) (41)
First-line treatment for advanced non-small-cell lung cancer. (2005) (41)
Phase I/II trial evaluating the anti-VEGF MAb bevacizumab in combination with erlotinib, a HER1/EGFR-TK inhibitor, for patients with recurrent non-small cell lung cancer. (2004) (40)
Prognostic factors for resected non-small cell lung cancer with pN2 status: implications for use of postoperative radiotherapy. (2009) (40)
A phase II study of cisplatin (P) plus etoposide (E) plus bevacizumab (B) for previously untreated extensive stage small cell lung cancer (SCLC) (E3501): A trial of the Eastern Cooperative Oncology Group (2007) (40)
Prospective correlative assessment of biomarkers in E4599 randomized phase II/III trial of carboplatin and paclitaxel ± bevacizumab in advanced non-small cell lung cancer (NSCLC). (2006) (39)
The activity of gemcitabine plus cisplatin in randomized trials in untreated patients with advanced non-small cell lung cancer. (1998) (39)
Safety and pharmacokinetic study of RPI.4610 (ANGIOZYME), an anti-VEGFR-1 ribozyme, in combination with carboplatin and paclitaxel in patients with advanced solid tumors (2005) (39)
Safety and pharmacokinetics (PK) of AMG 706, panitumumab, and carboplatin/paclitaxel (CP) for the treatment of patients (pts) with advanced non-small cell lung cancer (NSCLC). (2006) (39)
An evidence-based review of the incidence of CNS bleeding with anti-VEGF therapy in non-small cell lung cancer patients with brain metastases. (2012) (39)
LBA1_PRPrimary PFS and safety analyses of a randomized phase III study of carboplatin + paclitaxel +/− bevacizumab, with or without atezolizumab in 1L non-squamous metastatic nsclc (IMPOWER150) (2017) (39)
Steps and time to process clinical trials at the Cancer Therapy Evaluation Program. (2009) (38)
A population pharmacokinetic model for doxorubicin and doxorubicinol in the presence of a novel MDR modulator, zosuquidar trihydrochloride (LY335979) (2003) (38)
Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study. (2018) (38)
14LBA Atezolizumab monotherapy vs docetaxel in 2L/3L non-small cell lung cancer: Primary analyses for efficacy, safety and predictive biomarkers from a randomized phase II study (POPLAR) (2015) (37)
A phase II study of carboplatin plus gemcitabine in advanced non-small-cell lung cancer (NSCLC): a hoosier oncology group study. (1999) (37)
Cytoplasmic Clusterin Expression Is Associated with Longer Survival in Patients with Resected Non–Small Cell Lung Cancer (2007) (37)
Overview of the current status of human epidermal growth factor receptor inhibitors in lung cancer. (2004) (37)
O-277 CALGB 9732: Final report of a randomized phase III intergroup trial of etoposide(VP-16) and cisplatin (DDP) with or without paclitaxel(TAX) and G-CSF in patients with extensive stage small cell lung cancer(ED-SCLC) (2003) (37)
A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancy. (2004) (36)
Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study (2009) (35)
Two Drug Interaction Studies Evaluating the Pharmacokinetics and Toxicity of Pemetrexed When Coadministered with Aspirin or Ibuprofen in Patients with Advanced Cancer (2006) (35)
A phase II study of KOS-862 (epothilone D) as second-line therapy in non-small cell lung cancer (2005) (33)
A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Non–Small Cell Lung Cancer Based on Early Tumor Kinetics (2018) (33)
Genetic variants in angiogenesis pathway associated with clinical outcome in NSCLC patients (pts) treated with bevacizumab in combination with carboplatin and paclitaxel: Subset pharmacogenetic analysis of ECOG 4599. (2009) (33)
MA 05.09 Pre-Existing Immunity Measured by Teff Gene Expression in Tumor Tissue is Associated with Atezolizumad Efficacy in NSCLC (2017) (33)
Phase II study of daily oral etoposide plus ifosfamide plus cisplatin for previously treated recurrent small-cell lung cancer: a Hoosier Oncology Group Trial. (1995) (33)
A phase II trial of paclitaxel in refractory germ cell tumors (1998) (32)
Efficacy Analysis for Molecular Subgroups in MARQUEE: a Randomized, Double-blind, Placebo-controlled, Phase 3 Trial of Tivantinib (ARQ 197) Plus Erlotinib versus Placebo plus Erlotinib in Previously Treated Patients with Locally Advanced or Metastatic, Non-squamous, Non-small Cell Lung Cancer (NSCLC (2014) (31)
Classification by Mass Spectrometry Can Accurately and Reliably Predict Outcome in Patients with Non-small Cell Lung Cancer Treated with Erlotinib-Containing Regimen (2009) (31)
Angiogenesis in the treatment of non-small cell lung cancer. (2009) (31)
O-086a Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C)with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial — E4599 (2005) (31)
IMpower030: Phase III study evaluating neoadjuvant treatment of resectable stage II-IIIB non-small cell lung cancer (NSCLC) with atezolizumab (atezo) + chemotherapy. (2019) (30)
Randomized, phase III trial comparing irinotecan/cisplatin (IP) with etoposide/cisplatin (EP) in patients (pts) with previously untreated, extensive-stage (ES) small cell lung cancer (SCLC) (2005) (30)
Impact of atezolizumab (atezo) treatment beyond disease progression (TBP) in advanced NSCLC: Results from the randomized phase III OAK study. (2017) (30)
Systemic Therapy of Bronchioloalveolar Carcinoma: Results of the First IASLC/ASCO Consensus Conference on Bronchioloalveolar Carcinoma (2006) (30)
Retrospective study of clinical and radiographic risk factors associated with early onset, severe pulmonary hemorrhage in bevacizumab-treated patients with advanced non-small cell lung cancer (NSCLC). (2006) (30)
Phase II trial of bexarotene capsules in patients with advanced non-small-cell lung cancer after failure of two or more previous therapies. (2006) (29)
Bevacizumab in Non–Small Cell Lung Cancer (2007) (29)
Identifying barriers associated with enrollment of patients with lung cancer into clinical trials. (2013) (29)
Updated survival and biomarker analyses of a randomized phase II study of atezolizumab vs. docetaxel in 2L/3L NSCLC (POPLAR) (2016) (29)
ABX-EGF in combination with paclitaxel and carboplatin for advanced non-small cell lung cancer (NSCLC). (2004) (29)
Nondermatologic adverse events associated with anti-EGFR therapy. (2006) (29)
A phase I trial of gemcitabine plus paclitaxel combination therapy in patients with refractory solid tumors (1997) (29)
The safety of bevacizumab (2006) (28)
Effect of gender on outcome in two randomized phase III trials of paclitaxel poliglumex (PPX) in chemonaïve pts with advanced NSCLC and poor performance status (PS2). (2006) (28)
EGFR Tyrosine Kinase Inhibitors: Difference in Efficacy and Resistance (2013) (28)
Differential effect of age on survival in advanced NSCLC in women versus men: analysis of recent Eastern Cooperative Oncology Group (ECOG) studies, with and without bevacizumab. (2012) (28)
Phase II trial of gemcitabine in patients with previously untreated metastatic cancer of the esophagus or gastroesophageal junction. (2000) (27)
Baseline tumour measurements predict survival in advanced non-small cell lung cancer (2013) (27)
Epidermal Growth Factor Receptor Inhibitors and Antiangiogenic Agents for the Treatment of Non-Small Cell Lung Cancer (2009) (27)
Association of PD-L2 expression in human tumors with atezolizumab activity. (2016) (27)
Clinical experience with the HER1/EGFR tyrosine kinase inhibitor erlotinib. (2003) (26)
ABX-EGF in combination with paclitaxel and carboplatin for advanced non-small cell lung cancer (NSCLC) (2004) (26)
Clinical trials of MPDL3280A (anti-PDL1) in patients (pts) with non-small cell lung cancer (NSCLC). (2014) (26)
PL04a.02: OAK, a Randomized Ph III Study of Atezolizumab vs Docetaxel in Patients with Advanced NSCLC: Results from Subgroup Analyses (2017) (25)
OA14.02 IMpower131: Final OS Results of Carboplatin + Nab-Paclitaxel ± Atezolizumab in Advanced Squamous NSCLC (2019) (24)
EGFR and KRAS mutations in patients with bronchioloalveolar carcinoma treated with erlotinib in a phase II multicenter trial (2005) (24)
Phase II Study of Bendamustine in Relapsed Chemotherapy Sensitive or Resistant Small-Cell Lung Cancer (2014) (24)
Redefining bronchioloalveolar carcinoma. (2005) (23)
Ongoing and future trials of biologic therapies in lung cancer. (2003) (23)
A Phase 2 Randomized Trial of Paclitaxel and Carboplatin with or without Panitumumab for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer (2013) (22)
The rationale for adjuvant chemotherapy in stage I non-small cell lung cancer. (2007) (21)
A Phase II Study of Concurrent Chemoradiation with Weekly Docetaxel, Carboplatin, and Radiation Therapy Followed by Consolidation Chemotherapy with Docetaxel and Carboplatin for Locally Advanced Inoperable Non-small Cell Lung Cancer (NSCLC) (2009) (21)
1079 Gemcitabine plus cisplatin in non-small cell lung cancer: A phase II study (1995) (21)
Angiogenesis inhibition in the treatment of lung cancer. (2006) (21)
Non-classical response measured by immune-modified RECIST and post-progression treatment effects of atezolizumab in 2L/3L NSCLC: Results from the randomized phase II study POPLAR. (2016) (21)
OA03.02 Atezolizumab as 1L Therapy for Advanced NSCLC in PD-L1–Selected Patients: Updated ORR, PFS and OS Data from the BIRCH Study (2017) (21)
Phase I dose-escalation study of the anti-IGF-IR recombinant human IgG1 monoclonal antibody (Mab) IMC-A12, administered every other week to patients with advanced solid tumors (2007) (20)
Beyond bevacizumab: antiangiogenic agents. (2012) (20)
A phase II trial of paclitaxel in refractory germ cell tumors. (1998) (20)
Phase I trial of the combination of irinotecan, paclitaxel, and carboplatin in patients with advanced non-small-cell lung cancer. (2001) (20)
OA01.06 DETERRED: Phase II Trial Combining Atezolizumab Concurrently with Chemoradiation Therapy in Locally Advanced Non-Small Cell Lung Cancer (2018) (19)
Recent progress in therapeutic antibodies for cancer immunotherapy. (2018) (19)
ORAL01.04: Phase II Trial of Atezolizumab for Patients with PD‐L1–Selected Advanced NSCLC (BIRCH): Updated Efficacy and Exploratory Biomarker Results: Topic: Medical Oncology (2016) (19)
Current management of small cell lung cancer. (1997) (18)
Epidermal growth factor receptor inhibitors in lung cancer therapy. (2004) (18)
Novel agents in the treatment of lung cancer: conference summary statement. (2004) (18)
Phase II trial of irinotecan, paclitaxel and carboplatin in patients with previously untreated Stage IIIB/IV nonsmall cell lung carcinoma (2002) (18)
Irinotecan in cancers of the lung and cervix. (1999) (18)
Etoposide, ifosfamide and cisplatin (VIP) plus concurrent radiation therapy for previously untreated limited small cell lung cancer (SCLC): a Hoosier Oncology Group (HOG) phase II study. (2002) (18)
977 Phase I/II trial evaluating blockade of tumour blood supply and tumour cell proliferation with combined bevacizumab and erlotinib HCl as targeted cancer therapy in patients with recurrent non-small cell lung cancer (2003) (17)
An advance in small-cell lung cancer treatment--more or less. (2003) (17)
The importance of the eicosanoid pathway in lung cancer. (2003) (17)
Irinotecan therapy for small-cell lung cancer. (2002) (17)
Phase II trial combining atezolizumab concurrently with chemoradiation therapy in locally advanced non-small cell lung cancer. (2019) (17)
O-3 Randomized phase II study of the novel tubulin targetin agent, BMS-247550 (Epothilone B analogue) in the treatment of non-small cell lung cancer (NSCLC) in patients (pts) who have failed first line platinum containing therapy (2003) (17)
Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer. (2009) (16)
Beyond doublet chemotherapy for advanced non-small-cell lung cancer: combination of targeted agents with first-line chemotherapy. (2009) (16)
Cytoplasmic Clusterin Expression is Associated With Longer Survival in Patients With Resected Non-Small Cell Lung Cancer (2007) (16)
A Phase I Study of Weekly Gemcitabine and Docetaxel in Patients with Advanced Cancer: A Hoosier Oncology Group Study (2002) (16)
Risk of symptomatic central nervous system (CNS) progression and secondary hemorrhage in patients with non-squamous non-small cell lung cancer (NSCLC) receiving bevacizumab (BV)-based first-line therapy (2008) (16)
PD3-3-5: Outcomes for elderly advanced stage non-small cell lung cancer (NSCLC) patients (pts) treated with bevacizumab (B) in combination with carboplatin (C) and paclitaxel (P): Analysis of Eastern Cooperative Oncology Group (ECOG) 4599 study (2007) (15)
DETERRED: PD-L1 blockade to evaluate the safety of lung cancer therapy using carboplatin, paclitaxel, and radiation combined with MPDL3280A (atezolizumab). (2017) (15)
P-497 ZD6474 in combination with carboplatin and paclitaxel as first-line treatment in patients with NSCLC: Results of the run-in phase of a two-part randomized Phase II study (2005) (15)
Abstract CT076: IMpower150: Efficacy of atezolizumab (atezo) plus bevacizumab (bev) and chemotherapy (chemo) in 1L metastatic nonsquamous NSCLC (mNSCLC) across key subgroups (2018) (15)
A randomized phase II study of carboplatin with weekly or every-3-week nanoparticle albumin-bound paclitaxel (abraxane) in patients with extensive-stage small cell lung cancer. (2015) (15)
Facial diplegia as the presenting manifestation of acute lymphoblastic leukemia. (2001) (14)
Efficacy and safety of gefitinib (Iressa, ZD1839), an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with advanced non-small cell lung cancer (2003) (14)
An Open-Label, Multicenter, Three-Stage, Phase II Study of S-1 in Combination with Cisplatin as First-Line Therapy for Patients with Advanced Non-small Cell Lung Cancer (2011) (14)
MO06.12 Efficacy and safety of paclitaxel and carboplatin with bevacizumab for the first-line treatment of patients with nonsquamous non-small cell lung cancer (NSCLC): analyses based on age in the phase 3 PointBreak and E4599 trials. (2013) (13)
O-104 XYOTAXT™ vs. gemcitabine or vinorelbine for the treatment of performance status (PS) 2 patients with chemotherapy-naïve advanced non-small cell lung cancer (NSCLC): The STELLAR 4 Phase III study (2005) (13)
A sense of urgency: Evaluating the link between clinical trial development time and the accrual performance of CTEP-sponsored studies. (2009) (13)
Molecular targeted agents in non-small-cell lung cancer. (2003) (13)
Prospects and progress of atezolizumab in non-small cell lung cancer (2017) (13)
Congenital ependymoblastoma arising in the sacrococcygeal soft tissue: a case study. (2008) (12)
Analysis of prognostic factors in patients with advanced relapsed/refractory NSCLC: Cox regression analysis of a randomized phase III trial comparing docetaxel and paclitaxel poliglumex (PPX). (2006) (12)
A Phase II Study of Paclitaxel + Etoposide + Cisplatin + Concurrent Radiation Therapy for Previously Untreated Limited Stage Small Cell Lung Cancer (E2596): A Trial of the Eastern Cooperative Oncology Group (2009) (12)
A phase III, randomized, double-blind, placebo-controlled study of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated subjects with locally advanced or metastatic, nonsquamous, non-small cell lung cancer (NSCLC) . (2011) (12)
Novel Agents in the Treatment of Lung Cancer (2004) (12)
Phase I/II trial of bevacizumab plus erlotinib for patients with recurrent non-small cell lung cancer: Correlation of treatment response with mutations of the EGFR tyrosine kinase gene (2005) (12)
Molecular, immune and histopathological characterization of NSCLC based on PDL1 expression on tumor and immune cells and association with response to the anti-PDL1 antibody MPDL3280A. (2015) (12)
Outcomes for elderly advanced stage non-small cell lung cancer (NSCLC) patients (pts) treated with bevacizumab (B) in combination with carboplatin (C) and paclitaxel (P): Analysis of Eastern Cooperative Oncology Group (ECOG) 4599 study (2007) (12)
Long-term outcome of a phase II study of docetaxel-based multimodality chemoradiotherapy for locally advanced carcinoma of the esophagus or gastroesophageal junction (2011) (12)
Gemcitabine and paclitaxel combinations in non-small cell lung cancer. (1998) (12)
Patient-reported outcomes (PROs) in the randomized, phase III IMpower150 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous metastatic NSCLC (mNSCLC). (2018) (12)
Novel Agents in the Treatment of Lung Cancer: Fourth Cambridge Conference (2007) (11)
Ifosfamide in the treatment of advanced or recurrent squamous cell carcinoma of the head and neck: a phase II Hoosier Oncology Group trial. (1998) (11)
Incidence Trends of Lung Cancer by Immigration Status among Chinese Americans (2015) (11)
IMpower150: analysis of efficacy in patients (pts) with liver metastases (mets) (2019) (10)
Phase I study of irinotecan (Ir) and cisplatin (DDP) in combination with thoracic radiotherapy (RT), either twice daily (45 Gy) or once daily (70 Gy), in patients with limited (Ltd) small cell lung carcinoma (SCLC): Early analysis of RTOG 0241. (2006) (10)
A prospective comparison study of Endoscopic Ultrasound (EUS), Computed Tomography (CT) and EUS directed Fine Needle Aspiration biopsy (EUS/FNA) of the mediastinum in the preoperative staging of Non-Small Cell Lung Cancer (NSCLCA) (1995) (10)
Menopausal status of women may affect survival in advanced NSCLC: Analysis of recent Eastern Cooperate Oncology Group (ECOG) studies using age of 60 years or older as a surrogate marker: P1-052 (2007) (9)
PD3-3-7: Safety and Pharmacokinetics (PK) of AMG 706 With Carboplatin/Paclitaxel (C/P) and/or Panitumumab for the treatment of patients with advanced non-small cell lung cancer (NSCLC) (2007) (9)
Paclitaxel plus gallium nitrate and filgrastim in patients with refractory malignancies: a phase I trial. (1998) (9)
Irinotecan in small-cell lung cancer: the US experience. (2001) (9)
A sense of urgency: Evaluating the link between clinical trial development time and the accrual performance of CTEP-sponsored studies. (2009) (9)
Lung cancer: A review of current therapeutic modalities (2004) (9)
Lung Cancer Survival Among Chinese Americans, 2000 to 2010 (2016) (8)
Making Lung Cancer Clinical Trials More Inclusive: Recommendations for Expanding Eligibility Criteria (2018) (8)
A phase II study of carboplatin and irinotecan in extensive stage small-cell lung cancer. (2011) (8)
PS01.56: IMpower110: Phase III Trial Comparing 1L Atezolizumab with Chemotherapy in PD‐L1–Selected Chemotherapy‐Naive NSCLC Patients: Topic: Medical Oncology (2016) (8)
Polycythemia secondary to focal nodular hyperplasia. (1997) (8)
Phase III clinical trials in chemotherapy-naive patients with advanced NSCLC assessing the combination of atezolizumab and chemotherapy (2016) (8)
Accrual to clinical trials at selected comprehensive cancer centers (2008) (8)
Treatment of advanced (stages III and IV) non-small-cell lung cancer. (1998) (8)
Chemotherapy and antiangiogenic agents in non-small-cell lung cancer. (2007) (8)
Gemcitabine/Alimta in locally advanced or metastatic non-small-cell lung cancer. (2000) (7)
MALDI-TOF mass spectrometry proteomic profiling to discriminate response to the combination of bevacizumab and erlotinib in non-small cell lung cancer (NSCLC) (2005) (7)
State-of-the-art treatment for advanced non-small-cell lung cancer. (2003) (7)
PL02.07 IMpower 133: Primary PFS, OS and Safety in a PH1/3 Study of 1L Atezolizumab + Carboplatin + Etoposide in Extensive-Stage SCLC (2018) (7)
1322PBIOMARKERS ASSOCIATED WITH CLINICAL ACTIVITY OF PD-L1 BLOCKADE IN NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS (PTS) IN A PHASE I STUDY OF MPDL3280A. (2014) (7)
Karnofsky Performance Score as a Predictor of Survival in Soft Tissue Sarcoma (2002) (7)
OA 17.02 Updated Efficacy Results From the BIRCH Study: First-Line Atezolizumab Therapy in PD-L1–Selected Patients With Advanced NSCLC (2017) (7)
IMpower133: Primary efficacy and safety + CNS-related adverse events in a phase I/III study of first-line (1L) atezolizumab + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC). (2018) (7)
Targeting angiogenesis in lung cancer. (2005) (7)
A phase I pilot study of BCNU plus thymidine in patients with refractory cancer. (1996) (7)
O-109 Phase II trial of erlotinib in patients with bronchioloalveolarcarcinoma (2005) (6)
Carboplatin plus paclitaxel and sequential radiation followed by consolidation carboplatin and paclitaxel in patients with previously untreated locally advanced NSCLC. A Hoosier Oncology Group (HOG) phase II study. (2002) (6)
P2.17-27 IMpower030: Phase III Study Evaluating Neoadjuvant Treatment of Resectable Stage II-IIIB NSCLC with Atezolizumab + Chemotherapy (2018) (6)
A phase I dose-escalation and pharmacokinetic (PK) study of sunitinib (SU) plus docetaxel (D) in patients (pts) with advanced solid tumors (STs) (2007) (6)
Lung Cancer in the Elderly (2002) (6)
MA 10.03 3-Year Survival and Duration of Response in Randomized Phase II Study of Atezolizumab vs Docetaxel in 2L/3L NSCLC (POPLAR) (2017) (6)
First-line combination chemotherapy for advanced non-small cell lung cancer: the Eastern Cooperative Oncology Group and Southwest Oncology Group experience. (1999) (6)
Clinical course of advanced non-small cell lung cancer (NSCLC) patients (pts) experiencing hypertension (HTN) during treatment (TX) with bevacizumab (B) in combination with carboplatin (C) and paclitaxel (P) on E4599. (2009) (6)
PS01.53: First‐Line Atezolizumab Plus Chemotherapy in Chemotherapy‐Naive Patients with Advanced NSCLC: A Phase III Clinical Program: Topic: Medical Oncology (2016) (6)
A phase III trial to compare atezolizumab (atezo) vs best supportive care (BSC) following adjuvant chemotherapy in patients (pts) with completely resected NSCLC: IMpower010. (2017) (6)
Chemotherapy in metastatic non-small-cell lung cancer. (2000) (5)
Modeling and simulation of maintenance treatment in first-line non-small cell lung cancer with external validation (2016) (5)
OA 17.07 Long-Term Survival in Atezolizumab-Treated Patients with 2L+ NSCLC from Ph III Randomized OAK Study (2017) (5)
A Phase III study of atezolizumab with carboplatin plus etoposide in patients with extensive-stage small cell lung cancer (IMpower133) (2016) (5)
PS01.57: IMpower133: a Phase I/III Study of 1L Atezolizumab with Carboplatin and Etoposide in Patients with Extensive‐Stage SCLC: Topic: Medical Oncology (2016) (5)
P1.04-33 Retrospective Descriptive Analysis of Metformin with Atezolizumab in Advanced Non-Small Cell Lung Cancer in The OAK Trial (2018) (5)
Phase II trial of bexarotene capsules in patients with non-small-cell lung cancer (NSCLC) who have failed at least 2 prior systemic therapies for Stage IIIB/IV disease (2005) (5)
Irinotecan plus cisplatin in small-cell lung cancer. (2002) (5)
Systemic issues in small cell lung cancer. (2012) (5)
A Multicenter Phase II Study of Ganetespib Monotherapy in Patients with Genotypically De fi ned Advanced Non – Small Cell Lung Cancer (2013) (4)
P3.02c-041 IMpower133: A Phase I/III Study of 1L Atezolizumab with Carboplatin and Etoposide in Patients with Extensive-Stage SCLC (2016) (4)
Phase I/II trial of irinotecan, carboplatin, and paclitaxel in advanced or metastatic NSCLC. (2000) (4)
355TiPPhase III clinical trials of atezolizumab compared with standard chemotherapy in PD-L1–selected chemotherapy-naïve patients with advanced NSCLC (2015) (4)
Pharmacokinetic (PK) and pharmacodynamic analysis of aspirin administered with multi-targeted antifolate (ALIMTA) (2001) (4)
Paclitaxel (Taxol) plus doxorubicin plus filgrastim in advanced sarcoma: a phase II study. (1998) (4)
Irinotecan (CPT-11) in triplet combinations in patients with advanced non small-cell lung cancer: a review and report of a phase I/II trial. (2001) (4)
Analysis of prognostic factors in chemo-naïve patients with advanced NSCLC and poor performance status (PS): Cox regression analysis of two phase III trials. (2006) (4)
IMpower132: A phase III clinical program—1L atezolizumab plus platinum-based chemotherapy in chemo-naive advanced non-squamous NSCLC. (2017) (4)
Advanced non-small-cell lung cancer: new data, therapy choices, and challenging decisions. (2006) (4)
Abstract CT123: IMvoke010: Randomized Phase III study of atezolizumab as adjuvant monotherapy after definitive therapy of squamous cell carcinoma of the head and neck (SCCHN) (2019) (3)
Models of Lung Cancer Inhibitor AZD 2171 and Fractionated Radiotherapy in Mouse Vascular Endothelial Growth Factor Tyrosine Kinase (2006) (3)
P-565 A Phase II study of KOS-862 (Epothilone D) as second-linetherapy in non-small cell lung cancer (2005) (3)
Phase III clinical trials of atezolizumab combined with chemotherapy in chemotherapy-naive patients with advanced NSCLC. (2016) (3)
A phase I study of nab-paclitaxel (nP) with carboplatin (C) and thoracic radiation (TRT) in patients with locally advanced NSCLC. (2010) (3)
O-112 A phase I/II study of the anti-VEGF MAb bevacizumab (Avastin™) and erlotinib (Tarceva™), a HER1/EGFR-TK inhibitor: a multi-faceted approach for the treatment of recurrent non-small cell lung cancer (2003) (3)
Irinotecan: future directions in small-cell lung cancer. (2001) (3)
Effect of Carboxyamidotriazole Orotate, a Modulator of Calcium-Dependent Signaling Pathways, on Advanced Solid Tumors (2015) (3)
C-reactive protein reduction post treatment is associated with improved survival in atezolizumab (anti-PD-L1) treated non-small cell lung cancer patients. (2021) (3)
480TiP IMpower110: Phase III study on 1L atezolizumab (atezo) in PD-L1–selected chemotherapy (chemo)-naive NSCLC patients (pts) (2016) (3)
3017 NSCLC with high PD-L1 expression on tumor cells or tumorinfiltrating immune cells represents distinct cancer subtypes (2015) (3)
Gastrointestinal hemorrhage in advanced non-small cell lung cancer (NSCLC) patients treated with erlotinib and celecoxib. (2006) (3)
A prospective cost-effective evaluation of EUS directed fine needle aspiration biopsy (EUS+FNA) of mediastinal lymphadenopathy in the preoperative staging of non-small cell lung cancer (NSCLCA) (1996) (3)
The role of prophylactic cranial radiation in the treatment of non-small-cell lung cancer. (2003) (3)
Abstract A017: PD-L1 as a predictive biomarker for atezolizumab (MPDL3280A; anti-PDL1) in non-small cell lung cancer (NSCLC) (2016) (2)
Etoposide plus ifosfamide plus cisplatin in the treatment of small cell lung cancer. (1998) (2)
Abstract CT200: IMpower130: Progression-free survival (PFS) and safety analysis from a randomized phase 3 study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab as first-line (1L) therapy in advanced non-squamous NSCLC (2019) (2)
Phase III trial of paclitaxel (P), carboplatin (C), and irinotecan (CPT-11), in advanced or metastatic non-small-cell lung cancer (NSCLC) (1998) (2)
Lung Cancer Adjuvant Therapy (2007) (2)
Abstract A41: Analytic validation and clinical feasibility of a next-generation sequencing assay to assess tumor mutational burden from blood (bTMB) as a biomarker for anti-PD-L1 response in NSCLC (2018) (2)
PS01.62: Long‐Term Safety and Clinical Activity of Atezolizumab Monotherapy in Metastatic NSCLC: Final Results from a Phase Ia Study: Topic: Medical Oncology (2016) (2)
O-184 Bronchioalveolar carcinoma: Clinical characteristics and tissue microarray patterns (2003) (2)
CODE (cisplatin, vincristine, doxorubicin, etoposide) plus granulocyte colony-stimulating factor in advanced non-small-cell lung cancer: a Hoosier Oncology Group phase II trial. (1998) (2)
PS01.55: IMpower010: Phase III Study of Atezolizumab vs BSC After Adjuvant Chemotherapy in Patients with Completely Resected NSCLC: Topic: Medical Oncology (2016) (2)
The effect of smoking history on survival outcome: An exploratory analysis of a phase III study of gemcitabine and cisplatin in patients with advanced non-small cell lung cancer (NSCLC). (2006) (2)
143TiPIMpower110: Phase III trial of 1L atezolizumab in PD-L1–selected chemotherapy-naive NSCLC (2017) (2)
Phase I/III trial of atezolizumab with carboplatin and etoposide in ES-SCLC in first-line setting (IMpower133). (2017) (2)
Phase I dose-escalation study of thoracic irradiation with concurrent chemotherapy for patients with limited small cell lung cancer (LSCLC). Radiation therapy oncology group RTOG (2003) (2)
P-357 Cyclooxygenase-2 (COX-2) inhibition in advanced non-small cell lung cancer (NSCLC): preliminary results of a phase II trial (THO-0054) (2003) (2)
Irinotecan in small-cell lung cancer: current data and the status of ongoing trials. (2002) (2)
Phase I trial of pemetrexed plus oxaliplatin administered every other week in patients with metastatic cancer (2008) (2)
A phase III hoosier oncology group study of thoracic radiotherapy (TRT) plus cisplatin (P) and vinblastin (V) with or without hydroxgurea (HX) for locally unresectable non small cell lung cancer (NSCLC) (1998) (2)
356TiPPhase III clinical trials of atezolizumab in combination with chemotherapy in chemotherapy-naive patients with advanced NSCLC (2015) (2)
Altretamine for the Treatment of Metastatic Renal Cell Carcinoma – A Hoosier Oncology Group Trial (2004) (2)
Bevacizumab: Analysis of clinical benefit in females across trials in colorectal cancer and non-small cell lung cancer (2007) (2)
266 A phase II study of VP-16 plus ifosfamide plus cisplatin (VIP) plus concurrent radiation therapy (XRT) for previously untreated limited small cell lung cancer (SCLC): A Hoosier Oncology Group (HOG) trial (1997) (2)
Predictive value of serum MALDI-TOF proteomic profiling from patients treated with erlotinib and bevacizumab for survival in patients with non-small cell lung cancer (NSCLC) treated with erlotinib alone (2008) (1)
Efficacy, safety and predictive biomarker results from OAK, a randomized phase III study comparing atezolizumab with docetaxel in patients with advanced NSCLC (2017) (1)
Extensive small-cell lung cancer: a treatment overview. (2000) (1)
MS-4 Erlotinib in combination with bevacizumab for patients with recurrent non-small-cell lung cancer: a phase I/II trial (2004) (1)
Book Review Lung Cancer Third edition. Edited by Jack A. Roth, James D. Cox, and Waun Ki Hong. 468 pp., illustrated. Malden, MA, Blackwell, 2008. $169.95. 978-1-4051-5112-2 (2008) (1)
Introduction: Non-Small Cell Lung Cancer (2005) (1)
31 Differential efficacy and toxicity profiles of 4 different schedules of gemcitabine and cisplatin combination in non-small cell lung cancer (NSCLC) (1997) (1)
P-777 Phase I study of combination irinotecan and cisplatin and either twice daily thoracic radiation (45Gy) or once daily thoracic radiotherapy (70Gy) in patients with limited small cell lung carcinoma (SCLC): Early toxicity analysis of RTOG 0241 (2005) (1)
Urine PGE-M as a marker of intratumoral cyclooxygenase-2 activity in non-small cell lung cancer (NSCLC) (2004) (1)
Phase I Trial of Topotecan Plus Vinorelbine With/Without Filgrastim (G-CSF) in Patients With Refractory Malignancies (2002) (1)
Final results of a phase II trial of bexarotene capsules as 3rd or subsequent line therapy in patients with advanced non-small cell lung cancer (NSCLC). (2006) (1)
Urine PGE-M to assess prostaglandin E2 (PGE2) levels in non-small cell lung cancer (NSCLC). (2009) (1)
Efficacy and Safety of Single-Agent Axitinib (AG-013736; AG) in Patients with Advanced Non–Small-Cell Lung Cancer (NSCLC): A Phase II Trial (2007) (1)
Dose scheduling & drug tolerability in phase II studies of gemcitabine and cisplstin chemotherapy for non-small cell lung cancer (1997) (1)
429TiP IMpower010: A Phase III trial investigating atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy (chemo) in patients (pts) with completely resected NSCLC (2016) (1)
P3.02c-050 IMpower010: Phase III Study of Atezolizumab vs BSC after Adjuvant Chemotherapy in Patients with Completely Resected NSCLC: Topic: IT (2016) (1)
Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as ﬁ rst-line treatment in patients with advanced non-small-cell lung cancer (2012) (1)
Book Review Tumors of the Chest: Biology, Diagnosis and Management Edited by Konstantinos N. Syrigos, Chris M. Nutting, and Charis Roussos. 687 pp., illustrated. Berlin, Springer, 2006. $199. 978-3-540-31039-6 (2007) (1)
P1.01-052 Patient-Reported Outcomes (PROs) in OAK: A Phase III Study of Atezolizumab vs Docetaxel in Non-Small-Cell Lung Cancer (NSCLC) (2017) (1)
Abstract CT199: IMpower133: Primary efficacy and safety + CNS-related adverse events in a Ph1/3 study of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC) (2019) (1)
Implementation of a prospective screening tool for breast cancer clinical trial eligibility at an NCI designated cancer center. (2011) (1)
A Phase II Study of Celecoxib in Combination With Paclitaxel, Carboplatin, and Radiation Therapy for Patients With Inoperable Stage IIIA/B Non-Small Cell Lung Cancer (2007) (1)
Treatment of metastatic non-small-cell lung cancer. (2001) (1)
711 POSTER Sunitinib (SU) plus docetaxel (D) in patients (pts) with advanced solid tumors: a phase I dose-escalation and pharmacokinetic (PK) study (2007) (1)
P3.02c-038 First-Line Atezolizumab plus Chemotherapy in Chemotherapy-Naïve Patients with Advanced NSCLC: A Phase III Clinical Program: Topic: IT (2016) (1)
Angiogenesis Inhibitors in Lung Cancer (2010) (1)
P2.04-004 IMpower010: A Phase III Study of Atezolizumab vs Best Supportive Care Following Adjuvant Chemotherapy in Completely Resected NSCLC (2017) (1)
Atezolizumab as first-line therapy (1L) for advanced PD-L1-selected NSCLC patients: updated ORR, PFS, OS and exploratory biomarker results from the BIRCH study (2017) (1)
In reply [2] (2007) (0)
483TiP A Phase (Ph) III clinical program: 1L atezolizumab (atezo) plus chemotherapy (chemo) in chemo-naive advanced NSCLC (2016) (0)
tes and Ladders (2010) (0)
Bevacizumab in non-small cell lung cancer. Discussion (2007) (0)
58TiPIMpower133: Phase I/III trial of first-line atezolizumab with carboplatin and etoposide in ES-SCLC (2017) (0)
OA07.05 High-Grade Chemotherapy-Induced Peripheral Neuropathy (CIPN): An Analysis of ECOG-ACRIN Lung Cancer Clinical Trials (2019) (0)
Structural, infrastructural and procedural barriers to oncology clinical trials. (2004) (0)
Primary Sarcomas of the Lung (2012) (0)
554 POSTER Pharmacokinetic (PK) and pharmacodynamic (PD) results of Phase I studies of IMC-A12, a fully human insulin like growth factor-I receptor IgG1 monoclonal antibody, in patients with advanced solid malignancies (2008) (0)
The authors reply [5] (2007) (0)
Modeling and simulation of maintenance treatment in first-line non-small cell lung cancer with external validation (2016) (0)
O-142 Phase I and pharmacokinetic trial of inhalational doxorubicin (Resmycin™) (2003) (0)
6551 POSTER Efficacy and safety of single-agent axitinib (AG-013736; AG) in patients (pts) with advanced non-small cell lung cancer (NSCLC): a phase II trial (2007) (0)
Question-and-Answer Forum (2005) (0)
Development Of A Patient-Reported Outcome (Pro) Assessment Of Core Non-Small Cell Lung Cancer (Nsclc) Symptoms. (2015) (0)
In reply [9] (2007) (0)
Advanced Non-Small-Cell Lung Cancer (2006) (0)
A nonrandomized, multicenter, phase II study of S-1 with cisplatin as first-line therapy for patients with advanced non-small cell lung cancer (NSCLC). (2010) (0)
P-53 Phase I dose-escalation study of thoracic irradiation with concurrent chemotherapy for patients with limited small cell lung cancer (LSCLC). Radiation therapy oncology group (RTOG) protocol 9712 (2003) (0)
A phase I study of carboxyamidotriazole orotate (CTO) in of advanced solid tumors. (2013) (0)
O-156 Randomized, phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated, extensive-stage, small-cell lung cancer (SCLC) (2005) (0)
PD-143 Analysis of EGFr gene mutations in non-small cell lungcarcinoma (NSCLC) patients (pts) treated with panitumumab plus paclitaxel and carboplatin or chemotherapy alone (2005) (0)
Meaningful Subset Analyses Contribute to Optimal Patient Care (2008) (0)
Abstract 5707: On-treatment changes in CRP as a surrogate for overall survival for atezolizumab benefit in 2ndline NSCLC (2018) (0)
O-286 A phase II efficacy study of brostallicin, a novel minor groove binder (MGB), in patients (Pts) with platinum refractory or resistant non-small cell lung cancer (NSCLC) (2003) (0)
Eicosanoids in non-small cell lung cancer (NSCLC). (2010) (0)
Abstract B38: Lung cancer survival among Chinese Americans in California, 2000-2010 (2015) (0)
Pilot trial of molecular profiling and targeted therapies in advanced thoracic malignancies: Non-small cell lung cancer, small cell lung cancer and thymic malignancies (CUSTOM). (2012) (0)
A phase II study of concurrent chemoradiotherapy with weekly docetaxel, carboplatin, and radiation therapy followed by consolidation chemotherapy with docetaxel and carboplatin for locally advanced inoperable non-small cell lung cancer (2008) (0)
A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with docetaxel in patients with advanced solid tumors (2007) (0)
P-171 A phase I trial of gemcitabine, carboplatin or gemcitabine, paclitaxel and concurrent radiation therapy followed by consolidative gemcitabine and carboplatin for inoperable stage III non-small cell lung cancer: An RTOG study (2003) (0)
Pharmacokinetic Study of the Oral Histone Deacetylase Inhibitor , MS-275 , in Patients with Refractory SolidTumors and Lymphomas (2008) (0)
VP-16 plus ifosfamide plus cisplatin (VIP) in small cell lung cancer (1997) (0)
6570 POSTER Results for progression-free survival (PFS) from two randomised, double-blind, multicentre phase III studies of bevacizumab in combination with platin-based chemotherapy in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) are comparable when analysed by (2007) (0)
A timing and process flow analysis of opening clinical trials within an oncology cooperative group setting: The case of the CALGB. (2006) (0)
521TiP IMpower133: A phase I/III study of atezolizumab (atezo) with carboplatin (carbo) and etoposide as 1L therapy in patients (pts) with extensive-stage SCLC (ES-SCLC) (2016) (0)
Handbook of Advanced Cancer Care: Adult soft tissue sarcoma (2003) (0)
State-of-the-Art Treatment for Advanced NonSMQ-8211-SMQSmall-Cell Lung Cancer (2003) (0)
In reply [12] (2007) (0)
O-056 Survival differences by gender for patients with advancednon-small cell lung cancer in Eastern Cooperative Oncology Group trial 1594 (2005) (0)
Tyrosine Kinase Inhibitors of Angiogenesis (2007) (0)
Design of a phase II randomized, open-label trial of DN24-02, an autologous cellular immunotherapy targeting HER2/neu, in patients with surgically resected urothelial cancer at high risk of recurrence. (2011) (0)
Abstract A28: Incidence trends of lung cancer among Chinese Americans in California, 1990-2010 (2015) (0)
Antiangiogenesis in the treatment of NSCLC. Part 2 of a 3-part series: Targeting VEGF - Current and future research directions (2005) (0)
Efficacy and safety of single-agent axitinib (AG-013736; AG) in patients (pts) with advanced non-small cell lung cancer (NSCLC): a phase II trial (2008) (0)
Urine PGE-M as a marker of intratumoral cyclooxygenase-2 activity in non-small cell lung cancer (NSCLC). (2004) (0)
Enrollment of lung cancer patients on clinical trials at an NCI comprehensive cancer center. (2009) (0)
Association between baseline tumor dimensions and survival in advanced non-small cell lung cancer (NSCLC). (2013) (0)
The role of imaging studies in the work up of early stage melanoma (1992) (0)
P3.02c-042 IMpower110: Phase III Trial Comparing 1L Atezolizumab with Chemotherapy in PD-L1–Selected Chemotherapy-Naive NSCLC Patients: Topic: IT (2016) (0)
Practice Guidelines ( 2 nd Edition ) Stage IV : ACCP Evidence-Based Clinical Treatment of Non-small Cell Lung Cancer (2007) (0)
APhase II Study of Celecoxib in Combinationwith Paclitaxel, Carboplatin, and Radiotherapy for Patients with Inoperable Stage IIIA/BNon^Small Cell Lung Cancer (2009) (0)
P3-066: The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib (2007) (0)
Clinical Cancer esearch ial Report mmentary on Cheng et al . , p . 5557 se III Clinical Trial Development : A Process of R tes and Ladders (2010) (0)
Tumor genotype and clinical outcomes for 229 patients with non-small cell lung cancer. (2013) (0)
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab (2018) (0)
P-778 A phase II trial of carboplatin and irinotecan as first-line therapy for extensive stage small cell lung cancer (ES-SCLC): Preliminary results (2005) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Alan B. Sandler?

Alan B. Sandler is affiliated with the following schools:

Yale University
Indiana University
Vanderbilt University
University of Las Palmas de Gran Canaria
Oregon Health & Science University
Rush University
Duke University
University of Texas Southwestern Medical Center